« Previous AbstractDimethyl sulfide emission behavior from landfill site with air and water control    Next AbstractCatalytic destruction of chlorobenzene over K-OMS-2: Inhibition of high toxic byproducts via phosphate modification »

J Breath Res

Title:		High performance exhaled breath biomarkers for diagnosis of lung cancer and potential biomarkers for classification of lung cancer
Author(s):		Long Y; Wang C; Wang T; Li W; Dai W; Xie S; Tian Y; Liu M; Liu Y; Peng X; Liu Y; Zhang Y; Wang R; Li Q; Duan Y;
Address:		"Research Center of Analytical Instrumentation, Key Laboratory of Bio-source and Eco-environment, Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610065, People's Republic of China. West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, People's Republic of China. Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China. Graduate School, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China. College of Chemistry and Material Science, Northwest University, Xi'an, Shanxi 710127, People's Republic of China"
Journal Title:		J Breath Res
Year:		2021
Volume:		20210213
Issue:		1
Page Number:		16017 -
DOI:		10.1088/1752-7163/abaecb
ISSN/ISBN:		1752-7163 (Electronic) 1752-7155 (Linking)
Abstract:		"Exhaled breath analysis has emerged as a promising non-invasive method for diagnosing lung cancer (LC), whereas reliable biomarkers are lacking. Herein, a standardized and systematic study was presented for LC diagnosis, classification and metabolism exploration. To improve the reliability of biomarkers, a validation group was included, and quality control for breath sampling and analysis, comprehensive pollutants analysis, and strict biomarker screening were performed. The performance of exhaled breath biomarkers was shown to be excellent in diagnosing LC even in early stages (stage I and II) with surpassing 0.930 area under the receiver operating characteristic (ROC) curve (AUC), 90% of sensitivity and 88% of specificity both in the discovery and validation analyses. Meanwhile, in these two groups, diagnosing subtypes of LC attained AUCs over 0.930 and reached 1.00 in the two subtypes of adenocarcinomas. It is demonstrated that the metabolism changes in LC are possibly related to lipid oxidation, gut microbial, cytochrome P450 and glutathione S-transferase, and glutathione pathways change in LC progression. Overall, the reliable biomarkers contribute to the clinical application of breath analysis in screening LC patients as well as those in early stages"
Keywords:		"Area Under Curve Biomarkers, Tumor/*analysis Breath Tests/*methods Case-Control Studies Discriminant Analysis Environmental Pollutants/analysis *Exhalation Female Humans Least-Squares Analysis Lung Neoplasms/*classification/*diagnosis Male Middle Aged Neo;"
Notes:		"MedlineLong, Yijing Wang, Chunyan Wang, Tianzhi Li, Wenwen Dai, Wei Xie, Shaohua Tian, Yonghui Liu, Mingxin Liu, Yifeng Peng, Xiaoqin Liu, Yuanling Zhang, Yinchenxi Wang, Ruxin Li, Qiang Duan, Yixiang eng Research Support, Non-U.S. Gov't England 2021/02/16 J Breath Res. 2021 Feb 13; 15(1):016017. doi: 10.1088/1752-7163/abaecb"